1. Background {#sec1}
=============

Patients with complex hernias present surgeons with significant technical challenges. Over the past decade, a better understanding of abdominal wall anatomy, physiology and pathophysiology of hernia formation has resulted in the development of new surgical approaches focused on restoration of the midline and abdominal wall functionality, protection of intra-abdominal viscera, and the prevention of hernia or bulge formation post-operatively [@bib1].

First introduced 25 years ago by Ramirez [@bib2], over the past decade the technique of component separation has come to the forefront with clinicians presenting the approach as a means to achieve primary abdominal closure under minimal abdominal tension in difficult cases. The addition of mesh to reinforce the repair has been shown to decrease hernia recurrence rates [@bib3; @bib4; @bib5].

In recent years, a number of new prosthetic materials and surgical techniques have been introduced to address challenging hernias and most publications report series with variable approaches and mesh materials.

Early literature suggests that the placement of synthetic mesh runs a high risk of infection requiring subsequent removal and/or hernia recurrence [@bib6; @bib7]. Biologic mesh, suggested as an alternative for use in infected fields, has been associated with a high rate of long-term laxity and recurrence [@bib8; @bib9; @bib10; @bib11; @bib12; @bib13; @bib14; @bib15; @bib16].

With no randomized prospective trials reported, the heterogeneous nature of existing studies, specifically differences in patient characteristics, mesh selection and surgical approach, appears to contribute significantly to the wide range of post-operative outcomes [@bib17]. Surgeons are left struggling to draw conclusions related to optimal surgical technique and mesh selection.

Over the past several years, the authors have selected open component separation reinforced with a human acellular dermal mesh (Flex HD Musculoskeletal Transplant Foundation, Edison, NJ) to treat patients with complex abdominal wall defects. To assess the validity of our preferred approach, we prospectively studied a cohort of high-risk patients from our practice, treated in the same facility by a single surgeon.

2. Methods {#sec2}
==========

This is a prospective review of 19 consecutive high-risk patients, 8 males and 11 females, with large hernias repaired between July 2011 and July 2013. Prior to surgery, a detailed clinical assessment including a CT scan and cardiopulmonary evaluation was performed.

2.1. Surgical technique {#sec2.1}
-----------------------

Abdominal wall reconstruction was performed, decreasing tension across the midline using anterior and posterior component separation, and achieving primary closure in all cases. Depending on patient anatomy and risk profile, a selective periumbilical perforator sparing technique was used, particularly when the likelihood of skin necrosis was high.

Bilateral anterior component separation ([Fig. 1](#fig1){ref-type="fig"}) with intraperitoneal placement of a non-crosslinked human acellular dermal biologic mesh (*FlexHD, Musculoskeletal Transplant Foundation, Edison, NJ*) and midline closure was performed in the first 15 cases. The mesh, placed as an intraperitoneal underlay was prepared by delineating the four quadrants prior to implantation ([Fig. 2](#fig2){ref-type="fig"}). Using 1.0 PDS suture (*Ethicon, Somerville, NJ*), the mesh was secured to the anterior abdominal wall with interrupted vertical mattress stitches placed circumferentially to provide support and prevent small bowel entrapment ([Fig. 3](#fig3){ref-type="fig"}).

In the more recent 4 cases, posterior component separation ([Fig. 4](#fig4){ref-type="fig"}), involving release of the posterior sheet of the rectus muscle and preserving the abdominal wall innervation and epigastric circulation, was performed as described by Pauli and Rosen [@bib18]. In these cases, the biologic mesh was placed within the retrorectus space with overlap of at least 10 cm on each side of the midline and fixed in position with transfascial sutures ([Fig. 5](#fig5){ref-type="fig"}).

Following evaluation of mesh placement, midline approximation and debridement of the midline fascia was performed to obtain a well vascularized linea-alba. The midline was closed with running double loop 1.0 PDS suture. When posterior component separation was performed, the posterior fascia was closed using interrupted figure 8 1.0 vicryl sutures (*Ethicon, Somerville, NJ*) and the anterior fascia closed as described above.

During the course of this series, a newly shaped mesh, FlexHD^®^ Diamond™ was introduced. This shape was used in last 7 cases of our series. With a larger surface area due to its rhomboid shape, the surgeons found that it offered enhanced abdominal wall coverage and reduced operative time as no intraoperative shaping was required prior to use.

To minimize the risk of seroma and bleeding, meticulous hemostasis was performed and Evicel^®^ fibrin sealant (*Ethicon, Somerville, NJ*) and five grams of Arista^®^AH, a sterile, absorbable hemostatic powder (*Medafor, Inc. Minneapolis MN*) was administered. Two No. 19 closed-suction round drains were placed percutaneously and secured to the skin with 3.0 Nylon sutures (*Ethicon, Somerville, NJ*). A subcuticular closure was performed with Quill 3.0 Monoderm (Angiotech Pharmaceuticals, Inc. Vancouver, BC Canada). Drains were removed after 7--10 days and/or when the output was less than 20 cc daily.

Post-operative follow-up was scheduled at 2 weeks and subsequent 6 month intervals. The abdominal wall was assessed clinically and if there was any sign of hernia recurrence, a CT scan of the abdomen was performed.

2.2. Statistical analysis {#sec2.2}
-------------------------

Patient demographics, pre-existing medical comorbidities and surgical histories were collected prior to surgery. Following hernia repair, intraoperative characteristics, surgical techniques, short and longer-term outcomes, and reported complications were assessed. Data were summarized using descriptive statistics (means and standard deviation for continuous variables; count and frequency for categorical variables). Patient demographics and preoperative and intraoperative characteristics associated with increased post-operative complication risk were analyzed using the Mann--Whitney U test (for continuous variables) or Fisher exact test (for categorical data). Logistic regressions were conducted to identify preoperative and intraoperative variables predictive of major and minor complications. Because of the small sample size, Firth\'s penalized likelihood method was used to reduce sample bias in maximum likelihood estimation [@bib19]. The results of the univariate analysis were used to identify candidate variables for multivariate modeling. Because of the relatively small cohort of patients (n = 19), the multivariate analysis was limited to only include variables with p \< 0.1 in the univariate analysis. Based on the results of the univariate analysis, only one multivariate model with two independent variables (age and OR time) was performed for the minor complication outcome. Our post-hoc power analysis indicated that our sample size will yield an R^2^ of 0.32 in the univariate regression model and an R^2^ of 0.38 with two independent variables in multivariate analysis with 80% power. All statistical analyses were performed using SAS 9.4 statistical software (*SAS Inc., Cary, NC*).

3. Results {#sec3}
==========

3.1. Patient demographics {#sec3.1}
-------------------------

Nineteen consecutive patients, detailed in [Table 1](#tbl1){ref-type="table"}, underwent hernia repair with bilateral component separation and intraperitoneal and retrorectal placement of FlexHD^®^ or FlexHD^®^ Diamond™, human acellular dermal matrix mesh using an open abdominal approach. The cohort included 11 females and 8 males with mean patient age of 54.9 (range 41--76 yrs) and mean body mass index (BMI) of 29 kg/m^2^ (range 21.0--37.9). Besides large clinically significant abdominal wall hernias, patient histories included an array of chronic health conditions listed in [Table 2](#tbl2){ref-type="table"}. All patients had at least one pre-existing comorbidity, with 95% having two or more. The most common comorbidities included BMI \>25 (84%), hypertension (53%), and diabetes mellitus (42%).

3.2. Clinical presentation {#sec3.2}
--------------------------

Ten patients (52%) had failed prior hernia repair, six of whom had two prior recurrences. Thirteen patients (68%) had prior infections with 42% having a history of perforated bowel. Four patients (21%) presented with stomas. Patients were categorized using the Ventral Hernia Working Group classification system which is based upon risk factors for surgical site occurrences [@bib17]. The majority of patients in our series, 42%, were Grade 3 with 36% categorized as Grade 2 and 21% Grade 4. Baseline characteristics of the cohort are detailed in [Table 2](#tbl2){ref-type="table"}.

3.3. Operative course {#sec3.3}
---------------------

Upon entry into the abdomen, lysis of adhesions and removal of prior mesh implants was carried out as necessary. Upon inspection, the mean fascial defect to be repaired was 282 ± 70.5 cm^2^ (range 150--450) and the associated mean surface area of the biologic mesh we used to reinforce the repair was 454.3 ± 101.1 cm^2^ (range 160--521 cm^2^). Additionally, in two cases, concomitant small bowel resection was required. Mean operative time was 194 ± 63 min (range 127--360 min). Patients generally tolerated the procedure well and returned home after an average length inpatient stay of 4.6 ± 1.3 days (range 2--6). [Table 3](#tbl3){ref-type="table"} summarizes the intraoperative characteristics in the group.

3.4. Peri-operative outcomes {#sec3.4}
----------------------------

The majority (58%) of patients in our cohort had an uneventful recuperative course with no peri-operative complications (within 30 days).

The most frequent peri-operative events, which we consider minor complications, were superficial wound infections in six patients (32%). Additionally one seroma and one post-operative ileus, both occurring in a patient with a wound infection, were noted. Of the six wound infections, three were resolved with a course of oral antibiotics and the other 3 were treated in the office with incision and drainage of the wound. The one instance of seroma formation occurred several weeks after surgery. The seroma was drained under ultrasound at an office follow-up visit with complete resolution. Two patients experienced major complications; one developing a pulmonary embolism who was placed on six months of anti-coagulant therapy and the other with a hemorrhage requiring transfusion. Both patients recovered without further incident. Patient outcomes are summarized in [Table 4](#tbl4){ref-type="table"}.

Our series included highly complex cases. As an example, late in the series, an obese 80 year old female with 20 year history of recurrent hernia, presented with an enterocutaneous fistula, stoma and loss of abdominal domain ([Figs. 6 and 7](#fig6 fig7){ref-type="fig"}). Component separation using a retrorectus approach was performed. The patient experienced post-operative wound infection but the biologic mesh remained intact. At 18 months follow-up, a CT scan demonstrated an intact abdominal cavity with no evidence of hernia (Also see [Videos 1 and 2](#mmc1 mmc2){ref-type="supplementary-material"}).

The patient has fully recovered and a subsequent abdominal CT scan, performed relative to other medical conditions, revealed no evidence of recurrence.

The following is the supplementary video related to this article:Video 1CT scan preop of the patient 3-1-2013. The CT scan shows the loss of abdominal wall domain and the large ventral hernia.Video 2CT post op 9-3-2014.

Video 1 and Video 2: Video 1 shows the pre-operative CT scan. Video 2 shows the 18 month follow up CT scan of the reconstruction of the abdominal wall with retrorectus repair and intermuscular mesh placement.

3.5. Post-operative follow-up {#sec3.5}
-----------------------------

Nearly half (47%) of our patients are \>2 years post-treatment with patients followed for a median of 24 months post-repair (range 6--43 months). One patient expired one year after surgery as a result of pulmonary fibrosis unrelated to her hernia repair. Three recurrences (17%) were confirmed among the remaining 18 patients.

The first recurrence occurred in a 70 year old male who had a lengthy operation with removal of prior synthetic mesh implant. A peri-operative MRSA infection was cultured from one of his drains which responded well to local incision and drainage followed by antibiotic therapy. At 9 months following his repair, he developed bulging and an asymptomatic defect in the upper part of his abdomen. Of note was his clinical history of a severe MRSA infection and septic shock occurring after a previous hernia repair. For health reasons, the patient was advised to undergo no further procedures unless medically necessary.

The second recurrence was seen 12 months post-procedure in a very active 49 year old male who routinely plays basketball. Similar in nature to the first recurrence, an asymptomatic bulge was appreciated in his upper abdomen. The patient declined a repeat hernia repair and is being followed clinically.

The third recurrence was observed at 35 months follow-up. In this patient, the recurrence was noted in the inferior aspect of the wound. He returned for repeat surgery and a retrorectus repair was performed without any subsequent complications. Upon return to the OR, we found some of the original mesh, which was placed intraperitoneally, was loose within the peritoneal cavity. From observation, it appears that poor mesh integration inferiorly may have been a contributing factor to this recurrence.

3.6. Regression analysis {#sec3.6}
------------------------

To assess potential predictors of complication outcomes, we have grouped patient complications into major complications (including bleeding requiring transfusion and pulmonary embolism) and minor complications (including superficial wound infection, seroma requiring drainage and ileus). [Table 5](#tbl5){ref-type="table"} summarizes the results of univariate logistic regression analysis. Older age (OR = 1.07, 95% CI 1.02--1.17, p = 0.0483) and longer OR time (OR = 1.02, 95% CI 0.99--1.04, p = 0.0945) were associated with higher risk of minor complications at p \< 0.1. In the subsequent multivariate analysis including only age and OR time, however, only age remained a significant predictor of post-operative complications (OR = 1.12, 95% CI 1.06--1.32, p = 0.0324). No other variables were found to be predictive of recurrence or postoperative complications.

4. Discussion {#sec4}
=============

Understanding the underlying causes and variables associated with negative outcomes is critical so that efforts can be made to avoid landmines when a complicated operative path lies ahead. Since the early 1960s, the surgical community has sought to perfect hernia repair, and has been particularly challenged by complex cases when infection was present or anticipated.

Over time, studies have demonstrated mesh reinforced repairs offer superior outcomes versus primary repair [@bib20]. However, synthetic meshes can have significant complications and negative outcomes. An alternative was sought with desirable material characteristics including biocompatible, soft and flexible when implanted, infection resistant, and strong enough to withstand intra-abdominal pressures allowing patients an active lifestyle without hernia recurrence. When biologic mesh was introduced over a decade ago the hope was that it was the answer to all of these needs. Early experience, primarily cases in which the first allograft dermal matrix (ADM) available was placed as a bridge across large abdominal defects, reported significant recurrent bulging at follow-up [@bib12; @bib13]. Many biologic mesh products have followed including other allografts and a range of xenograft derived materials. Each is manufactured using different processing techniques. Recent literature suggests that ADM biologic mesh should be the material of choice when encountering wound infections and contamination [@bib21].

In addition to a plethora of new mesh options, new surgical techniques for abdominal wall reconstruction have emerged. Few studies exists evaluating these advances in controlled settings and recently some have suggested that operative technique may have more influence on outcomes than mesh selection, but that has not been demonstrated in a systematic manner [@bib22]. Thus, surgical approach and mesh selection remain a matter of surgeon preference with no definitive data to conclusively support one over another. After reviewing the literature along with personal surgical outcomes, the authors now choose to repair complex hernias using an open abdominal component separation reinforced with a non-crosslinked human acellular dermal mesh, FlexHD. While we have used the rectangular shape in some cases, when available, we prefer to use the diamond shape which allows for wider anatomic coverage. As has been reported, we believe tension-free closure of the midline is critical to achieve positive surgical outcomes [@bib23].

While surgeons have control over their operative approach and mesh selection, there are variables which affect outcomes that are beyond a surgeons\' scope. It is important, however, for surgeons to understand and recognize these variables and take steps to mitigate their influence over outcomes whenever possible. A number of studies have described an increased risk, reported up to 4× greater, of infection related to individual comorbidities. Analyses have suggested older age, obesity, smoking, coronary artery disease, corticosteroid use, prolonged operative time and pulmonary disease as several independent predictors for infections [@bib24]. Even in our small series, increased age and OR time were found to be statistically independent predictors of minor complications, the majority of which were wound infections.

We saw a low rate of seroma formation (n = 1, 5%), that we speculate is attributed to our surgical protocol which includes use of Evicel fibrin glue, active prophylaxis regimen and the use of large bore drains. Köhler et al. also reported a reduction of seroma formation when Evicel was used. In their series of 60 patients who underwent open ventral hernia repair, half were treated with fibrin glue and the other half served as controls treated without fibrin glue. In addition to a significant reduction in seroma formation, the authors noted a related shorter length of stay in the treatment group [@bib25].

In a review of ventral hernia recurrence, Awad et al. estimated that greater than 75% of all recurrence is due to infection and inadequate repair material fixation and/or overlap [@bib26]. Similarly, in our series, 68% of our recurrences (2 of 3) were patients who experienced a post-operative wound infection. During reoperation for the third recurrence, upon inspection, the authors observed poor biologic integration resulting from suboptimal mesh positioning. Therefore it was our technique, as opposed to the inherent properties of the bioprosthetic, which likely contributed to this negative outcome. During the course of this series, the authors modified our approach and performed a posterior component separation on the final four cases. We placed the FlexHD Diamond mesh in the retrorectus space and to date with 15--25 month follow-up, no recurrences have been seen in these cases.

We believe that our findings are a promising indicator that disproves the perception that all human acellular dermal meshes are an unacceptable choice for complex hernia repair due to a propensity for long-term bulging. Existing literature reviews include a heterogeneous mix of patient sets, biologic mesh materials and surgical techniques [@bib13]. The current study, comprised of complex patients with large hernia repairs reinforced exclusively with FlexHD, showed a clinically acceptable recurrence rate of 16% at a median 2-years follow-up, comparing favorably to similar reports of other biologic and synthetic mesh materials [@bib9; @bib11; @bib26; @bib27; @bib28; @bib29; @bib30; @bib31]. We are encouraged by this outcome, as the majority of our patients had experienced prior hernia recurrence, putting them at greater risk for future recurrence.

With the population aging and more baby boomers entering their senior years, it is important to consider the inherent risks associated with older patients. We feel age may be an indication for the utilization of a biologic mesh as older patients are inherently prone to higher risk of infection. As identified in our analyses, older age was predictive of minor complications, yet in all cases, these events were resolved without costly operative intervention, extended in-patient care or long term clinical sequelae. We consider these results as suggestive that use of a biologic mesh may reduce the overall cost of care of complex hernias particularly in high-risk older patients. We theorize that long-term savings from the use of biologic mesh may far outweigh their upfront costs in this patient subset. This assumption, of course, must be demonstrated across a larger patient cohort in a well-designed controlled clinical trial.

5. Conclusions {#sec5}
==============

There is no clear-cut standard protocol to treat patients who present with complex abdominal wall defects. Surgeons need to evaluate individual patient characteristics and have an understanding of anatomy and various mesh materials in order to select the most appropriate operative course.

Our series demonstrates that an open component separation reinforced with a human biologic mesh, FlexHD, and complete midline closure is a safe, viable approach that achieves desirable short and mid-term outcomes. Patients in our series were at high risk for post-operative infection due to comorbidities or prior infection and did quite well with follow-up beyond 2 years.

Continued long-term assessment of this cohort is planned and a controlled prospective trial directly comparing our current technique and the Rives Stoppa technique with different mesh materials is being considered.

6. Limitations {#sec6}
==============

We recognize the limitations of our series, specifically, the small number of cases, non-randomization and lack of a control group. While the technique described here produced outcomes which are comparable or better than other experiences reported in the literature, controlled studies to compare specific surgical approaches and mesh materials and assess clinical outcomes are needed and would further contribute to the existing body of knowledge on use of reinforcing matrices in complex hernia repair.
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![**Anterior component separation technique**: the aponeurosis of the external oblique muscle is incised to 1--2 cm lateral to the lateral border of the rectus abdominus muscle as indicated by the arrow. The anterior component separation is performed bilaterally to decrease abdominal wall tension during subsequent midline closure.](gr1){#fig1}

![**Preparation of the mesh**: to ensure proper size and placement, the mesh is measured and each of the quadrants marked prior to its introduction into the abdominal cavity (white arrow). In this figure we show the new diamond shape mesh (FlexHD^®^ Diamond™).](gr2){#fig2}

![**Intraperitoneal placement of human acellular dermal matrix**: this figure shows the U-stitch that is placed through the abdominal wall to the mesh and back to the abdominal wall (see arrow).](gr3){#fig3}

![**Posterior component separation**: in this figure the right angle retractor is placed in the internal oblique aponeurosis while it is divided (green arrow). The blue arrow represents the posterior rectus sheet together with the transverse abdominis muscle. The white arrow indicates the rectus muscle seen inferiorly.](gr4){#fig4}

![**Mesh fixation**: the fixation of the mesh transfacially is accomplished by inserting the Reverdin needle (white arrow) percutaneously through the skin, subcutaneous tissue and anterior fascia and picking the stitches previously placed in the mesh in a U fashion (black arrow).](gr5){#fig5}

![80 yo female with a 20 year history of recurrent hernia presenting with an enterocutaneous fistula, stoma and loss of abdominal domain.](gr6){#fig6}

![Follow-up at 18 months after posterior component separation reinforced with ADM in the retrorectus space.](gr7){#fig7}

###### 

Detailed demographics, characteristics and outcomes of each individual patients.

  Patient\#   Demographics       Post operative complication                                                
  ----------- -------------- --- ----------------------------- --- ---- ----- ----- ----- ----- ----- ----- ---------------------------------------
  1           45             F   27.0                          1   42   No    No    No    No    No    No    No
  2           41             M   34.0                          2   24   No    No    No    No    No    No    No
  3           45             M   27.0                          2   43   No    Yes   No    No    No    No    No
  4           76             M   23.0                          6   41   No    No    Yes   No    No    No    No
  5           75             F   28.0                          4   17   No    Yes   No    No    No    No    No
  6           49             M   28.5                          2   12   Yes   No    No    No    No    No    No
  7           45             M   27.5                          3   32   No    Yes   No    Yes   Yes   No    No
  8           49             F   28.0                          4   25   No    No    No    No    No    Yes   No
  9           70             M   27.0                          5   9    Yes   Yes   No    No    No    No    No
  10          43             M   37.9                          3   35   Yes   No    No    No    No    No    No
  11          51             F   22.2                          2   30   No    No    No    No    No    No    No
  12          52             F   28.3                          2   6    No    No    No    No    No    No    No
  13          59             F   33.4                          4   12   No    No    No    No    No    No    No
  14          40             F   30.0                          5   30   No    No    No    No    No    No    No
  15          59             F   21.0                          3   12   No    No    No    No    No    No    Yes[a](#tbl1fna){ref-type="table-fn"}
  16          51             M   36.0                          2   24   No    No    No    No    No    No    No
  17          59             F   35.0                          2   25   No    No    No    No    No    No    No
  18          80             F   28.0                          2   23   No    Yes   No    No    No    No    No
  19          55             F   41.0                          3   11   No    Yes   No    No    No    No    No

Patient died of pulmonary fibrosis unrelated to the surgery.

###### 

Baseline characteristics of the 19 patients in the series.

  Characteristics                            N             \%
  ------------------------------------------ ------------- -------
  **Demographics**                                         
  Age (yr), \[mean ± sd\]                    54.9 ± 12.3   
  BMI (kg/m^2^), \[mean ± sd\]               29.6 ± 5.3    
  Gender (female), %                         11            57.9
  **Comorbidity**                                          
  Any pre-existing comorbidity               19            100.0
  -with 1 pre-existing comorbidity           1             5.3
  -with 2 or more pre-existing comorbidity   18            94.7
  Smoking                                    1             5.3
  Overweight or obese (BMI ≥ 25 kg/m^2^)     16            84.2
  Diabetes                                   8             42.1
  HTN                                        10            52.6
  CAD                                        1             5.3
  History of cancer                          5             26.3
  COPD                                       3             15.8
  On steroid                                 2             10.5
  Renal failure                              1             5.3
  Rheumatoid arthritis                       1             5.3
  GERD                                       1             5.3
  Hypothyroidism                             1             5.3
  **Clinical characteristics**                             
  Previous recurrence                        10            52.6
  -with one previous recurrence              4             21.1
  -with two previous recurrence              6             31.6
  Previous infection                         13            68.4
  Hernia grade ≥ 3                           12            63.2
  1                                          0             0.0
  2                                          7             36.8
  3                                          8             42.1
  4                                          4             21.1

###### 

Intra-operative patient characteristics.

  Characteristics                         N           \%
  --------------------------------------- ----------- ------
  Mesh removed                            6           31.6
  Ostomy present                          4           21.1
  H/O perforated bowel                    8           42.1
  Size of defect (cm^2^), \[mean ± sd\]   282 ± 79    
   Defect ≥ 300 cm^2^                     8           42.1
  Surgical techniques                                 
   Underlay                               7           36.8
   Underlay/Overlay                       4           21.1
   Diamond underlay                       4           21.1
   Retrorectus                            4           21.1
  Mesh area (cm^2^), \[mean ± sd\]        454 ± 95    
   Area ≥ 500 cm^2^                       12          63.2
  Perforator sparing                      7           36.8
  OR time (min), \[mean ± sd\]            194 ± 63    
  Length of stay (day), \[mean ± sd\]     5.3 ± 3.2   

###### 

Postoperative follow-up details.

  Complications                                        N          \%
  ---------------------------------------------------- ---------- --------
  **Median follow-up time (month)**                    24 month   
  \< 1 yr                                              3          15.8
  1--2 yr                                              7          36.8
  2--3 yr                                              6          31.6
  3--4 yr                                              3          15.8
  **Post-operative complications**                                
  Superficial wound infection                          6          31.6
  -Wound infection needing ID                          3          15.8
  Seroma requiring drainage                            1          5.3
  Post-operative ileus                                 1          5.3
  Post-operative flap bleeding requiring transfusion   1          5.3
  Pulmonary embolism                                   1          5.3
  Recurrence                                           3          15.8
  Death[a](#tbl4fna){ref-type="table-fn"}              1          5.3
  *Patient with no complications*                      *11*       *57.9*

1 patient died of pulmonary fibrosis unrelated to surgery.

###### 

Univariate logistic regression for post-operative complication and recurrence.

  Predictor                        Recurrence          Major complication   Minor complication                                
  -------------------------------- ------------------- -------------------- -------------------- -------- ------------------- ------------
  **Demographics**                                                                                                            
  Age                              0.99 (0.89--1.10)   0.8813               1.05 (0.94--1.18)    0.3668   1.07 (1.02--1.17)   **0.0483**
  BMI                              1.07 (0.85--1.35)   0.5856               0.79 (0.52--1.19)    0.2595   1.01 (0.84--1.21)   0.9413
  Gender (female)                  0.07 (0.01--1.82)   0.1089               0.70 (0.04--13.2)    0.8117   0.63 (0.09--4.40)   0.6369
  **Comorbidity (%)**                                                                                                         
  Number of comorbidity            1.25 (0.50--3.09)   0.6309               4.56 (0.77--27.1)    0.0956   1.15 (0.55--2.40)   0.7047
  Overweight or obese              1.81 (0.05--8.39)   0.7477               1.82 (0.34--13.4)    0.2186   4.33 (0.12--15.3)   0.4204
  Smoking                          1.53 (0.02--15.8)   0.8588               25.1 (0.28--68.2)    0.1499   0.62 (0.01--6.59)   0.8407
  Diabetes                         3.48 (0.32--37.8)   0.3050               1.77 (0.13--23.7)    0.6666   0.32 (0.03--2.89)   0.3066
  HTN                              4.63 (0.41--32.9)   0.2151               14.8 (0.52--43.6)    0.1155   1.17 (0.15--8.98)   0.8781
  CAD                              1.53 (0.02--15.8)   0.8588               25.1 (0.28--68.2)    0.1499   0.62 (0.01--65.9)   0.8407
  History of cancer                3.30 (0.23--8.99)   0.4867               20.7 (0.68--63.1)    0.1821   0.58 (0.06--5.72)   0.6376
  COPD                             0.83 (0.02--41.3)   0.9248               1.24 (0.02--65.4)    0.9154   2.27 (0.12--43.7)   0.5865
  On steroid                       0.83 (0.02--41.3)   0.9248               1.24 (0.02--65.4)    0.9154   2.27 (0.12--43.7)   0.5865
  Renal failure                    1.53 (0.02--15.8)   0.8588               25.1 (0.28--68.2)    0.1499   0.62 (0.01--65.9)   0.8407
  Rheumatoid arthritis             1.53 (0.02--15.8)   0.8588               2.27 (0.02--24.8)    0.7319   7.26 (0.07--74.3)   0.4007
  GERD                             19.6 (0.18--72.1)   0.2163               2.27 (0.02--24.8)    0.7319   7.26 (0.07--74.3)   0.4007
  Hypothyroidism                   19.6 (0.18--72.1)   0.2163               2.27 (0.02--24.8)    0.7319   7.26 (0.07--74.3)   0.4007
  **Pre-operative**                                                                                                           
  Previous infection               0.80 (0.07--8.89)   0.8539               0.07 (0.01--1.94)    0.1155   11.3 (0.42--30.3)   0.1494
  Previous recurrence              0.48 (0.05--4.98)   0.5338               0.14 (0.01--4.02)    0.2529   5.67 (0.62--51.7)   0.1240
  **Intra-operative**                                                                                                         
  Mesh removed                     1.25 (0.11--13.9)   0.8539               0.35 (0.01--10.8)    0.5510   8.27 (0.93--74.1)   0.1587
  Ostomy present                   0.40 (0.01--12.9)   0.6035               0.60 (0.02--20.9)    0.7780   2.56 (0.27--24.5)   0.4160
  H/O perforated bowel             0.76 (0.07--8.06)   0.8196               0.22 (0.01--6.42)    0.3817   1.55 (0.23--10.6)   0.6579
  Hernia grade ≥ 3                 0.55 (0.01--8.39)   0.1779               0.57 (0.04--7.58)    0.6666   1.17 (0.16--8.54)   0.8808
  Defect ≥ 300 cm^2^               2.69 (0.25--28.6)   0.4115               1.40 (0.11--18.5)    0.7982   3.80 (0.51--28.3)   0.1929
  Surgical techniques                                                                                                         
   Diamond vs. underlay            4.33 (0.28--66.3)   0.2922               6.42 (0.15--26.8)    0.3286   0.94 (0.07--13.6)   0.9656
   Underlay/Overlay vs. underlay   0.48 (0.01--21.1)   0.7046               6.42 (0.15--26.8)    0.3286   0.94 (0.07--13.6)   0.9656
   Retro vs. underlay              0.48 (0.01--21.1)   0.7046               1.67 (0.02--14.6)    0.8230   2.20 (0.18--27.6)   0.5413
  Mesh area ≥500 cm^2^             5.53 (0.20--15.2)   0.3122               3.57 (0.12--14.8)    0.4604   1.17 (0.16--8.54)   0.8808
  Perforator sparing                                                                                                          
   OR time                         0.99 (0.96--1.02)   0.3698               0.99 (0.98--1.02)    0.9466   1.02 (0.99--1.04)   **0.0945**
   Length of stay                  0.54 (0.19--1.54)   0.2458               1.02 (0.66--1.58)    0.9307   1.73 (0.82--3.64)   0.1498

Major complication: bleeding requiring transfusion and pulmonary embolism.

Minor complication: superficial wound infection, Seroma requiring drainage, and ileus.

OR = odds ratio; CI = confidence interval.
